Skip to main content

Home/ Cancer/ Group items tagged T-regs

Rss Feed Group items tagged

Matti Narkia

T-helper/T-regulator lymphocyte ratio as a new immunobiological index to quantify the a... - 0 views

  •  
    T-helper/T-regulator lymphocyte ratio as a new immunobiological index to quantify the anticancer immune status in cancer patients. Brivio F, Fumagalli L, Parolini D, Messina G, Rovelli F, Rescaldani R, Vigore L, Vezzo R, Vaghi M, Di Bella S, Lissoni P. In Vivo. 2008 Sep-Oct;22(5):647-50. PMID: 18853761 RESULTS: The mean TH/TR ratio observed in patients with metasytases was significantly lower with respect to that found in both patients without metastases and controls. On the contrary, the absolute mean number of T-reg cells was higher in patients with metastases than in those without, but the difference was not statistically significant. CONCLUSION: The evaluation of T-reg cells in terms of their proportion with respect to T-helper cell total number seems to be more appropriate than the simple measurement of their absolute count, in order to quantify cancer-related immunosuppression. Thus, the TH/TR ratio could represent a useful biological marker to explore the immune status of cancer patients.
Matti Narkia

Interleukin 2-mediated conversion of ovarian cancer-associated CD4+ regulatory T cells ... - 0 views

  •  
    Interleukin 2-mediated conversion of ovarian cancer-associated CD4+ regulatory T cells into proinflammatory interleukin 17-producing helper T cells. Leveque L, Deknuydt F, Bioley G, Old LJ, Matsuzaki J, Odunsi K, Ayyoub M, Valmori D. J Immunother. 2009 Feb-Mar;32(2):101-8. PMID: 19238008 doi: 10.1097/CJI.0b013e318195b59e Thus, although the impact of TH17 cells on the evolution of EOC remains to be established, our data suggest that local IL-2 treatment in ovarian cancer may result in the conversion of tumor-associated Treg into TH17 cells, relieve Treg-mediated suppression, and contribute to enhance antitumor immunity.
Matti Narkia

Multiple roles for CD4+ T cells in anti-tumor immune responses. - Wiley InterScience ::... - 0 views

  •  
    Multiple roles for CD4+ T cells in anti-tumor immune responses. Kennedy R, Celis E. Immunol Rev. 2008 Apr;222:129-44. Review. PMID: 18363998 DOI: 10.1111/j.1600-065X.2008.00616.x
Matti Narkia

Inhibition of suppressor T lymphocytes (Ts) by cimetidine. - J Immunol. 1987 May - 0 views

  •  
    Inhibition of suppressor T lymphocytes (Ts) by cimetidine. Sahasrabudhe DM, McCune CS, O'Donnell RW, Henshaw EC. J Immunol. 1987 May 1;138(9):2760-3. PMID: 2952721 Cyclophosphamide (CY) is the most extensively studied inhibitor of suppressor T lymphocyte (Ts) function. However, repeated administration of CY can abrogate sensitization. Therefore, we were interested in identifying noncytotoxic inhibitors of Ts function as adjuncts in the immunotherapy of Ts-inducing murine tumors. The effect of cimetidine (a histamine type 2 receptor antagonist) and diphenhydramine (a histamine type 1 receptor antagonist) on the Ts mediating tolerance to 2,4-dinitrofluorobenzene was studied. We report our data regarding the specific inhibition of Ts by cimetidine.
Matti Narkia

The inflammatory Th 17 subset in immunity against self and non-self antigens - Autoimmu... - 0 views

  •  
    The inflammatory Th 17 subset in immunity against self and non-self antigens. Jin D, Zhang L, Zheng J, Zhao Y. Autoimmunity. 2008 Mar;41(2):154-62. Review. PMID: 18324485 DOI: 10.1080/08916930701776605
1 - 5 of 5
Showing 20 items per page